The U.S. Department of Health and Human Services defines mHealth as “the use of mobile and wireless devices to improve health outcomes, healthcare services, and health research.” At BBK, we call it a priority.
This is the final installment of our interview with the Drug Information Association (DIA) about the their Patient Advocate Fellowship Program. To read part one of this two-part series, click here.
At this year’s Annual Meeting of the Drug Information Association (DIA), my colleague Jackie and I had the pleasure of meeting with representatives from the DIA Patient Advocate Fellowship Program. The program was designed to strengthen patient collaborations with industry players and to raise awareness of patient groups. Now in its third year, the program has successfully “graduated” more than fifty Patient Fellows. Needless to say, Jackie and I felt compelled to reach out to the DIA for a special blog interview to learn more. Here’s what they had to say…
Here at BBK, we’re always musing over innovative ideas for using social media in patient recruitment. But we know this has been the Achilles’ heel of the pharma industry since the beginning of time, and we get it – industry players are discouraged by IRB / EC regulations and even more discouraged by what patients might say about their brand on social media networks.
Social media listening programs observe and track social media activity, providing insights difficult to gather otherwise. When implemented in a patient recruitment campaign, these programs can gather information around a specific disease or condition, identifying active advocacy groups, common treatments, and challenges facing patients. But it goes even deeper than that, enabling you to implement the right strategies to speed your enrollment efforts.
The 49th Annual Meeting of the Drug Information Association is right around the corner, and per usual, BBK likes to check in with the conference organizers to see what’s in store for the attendees this year. At last year’s conference, I had the pleasure of meeting Courtney Ingram, Manager DIA North America Marketing. A few days ago, Courtney and I had the chance to reconnect about this year’s conference. So, without further ado, here’s my conversation with Courtney Ingram...
BBK Worldwide, a global leader in patient recruitment, has launched Health Info Gizmo (the Gizmo), a mobile vehicle used to inform, educate, and engage patient audiences about clinical trials, and in the process, foster long-term relationships between advocacy groups and the pharmaceutical industry. By leveraging the power of collaboration, the Gizmo provides clinical trial sponsors with opportunities to engage and partner with patient advocacy organizations to advance clinical research. “Advocacy groups are hesitant to assist in the promotion of clinical trials for fear that their involvement may smatter of endorsement of one company or therapeutic direction over another,” said Aaron B. Fleishman, leader of BBK’s social innovation group. “The interesting dilemma is that, more than ever, advocacy groups want to help their constituencies by encouraging awareness of clinical trials.”
Lasting relationships with patient advocacy and community groups can be an important part of a patient recruitment program. The question is, how do you build those relationships? And once you’ve built them, how do you maintain them? Here are a few ways you can work with advocacy groups as a patient recruitment tactic.
Last week, I attended the 4th Annual Summit for Clinical Ops Executives (SCOPE) conference in Miami. Unfortunately, I didn’t get as tan as I hoped; however, I did have the opportunity to lead a roundtable discussion on social media in the patient recruitment industry. This wasn’t my first rodeo. While we were discussing patient recruitment and social media, it struck me that people are done talking about it and want to start doing it. While I’m completely on board with that idea, the question still remains, “How?”
Social media has provided an unparalleled new channel of communication for clinical research sponsors in search of study participants. No matter the size or scope of the clinical trial, social media gives sponsors the unprecedented and powerful ability to: